## Abstract ## Background Adiponectin (Adipo), an adipocyte hormone involved in the regulation of glucose and lipid metabolism, has already been identified as a potential therapeutic target for the treatment of diabetes. However, successful delivery of Adipo to the receptors is difficult due to th
Gene therapy of streptozotocin-induced diabetes by intramuscular delivery of modified preproinsulin genes
✍ Scribed by France Croze; Dr Gérald J. Prud'homme
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 366 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1099-498X
- DOI
- 10.1002/jgm.359
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
Despite improvements in insulin preparation and delivery, physiological normoglycemia is not easily achieved in diabetics. Therefore, there has been considerable interest in developing gene therapy approaches to supply insulin. We studied a nonviral muscle‐based method of gene therapy and demonstrated that it could prevent hyperglycemia in murine streptozotocin (STZ)‐induced diabetes.
Methods
A plasmid encoding mouse furin‐cleavable preproinsulin II cDNA (FI), or its B10‐analogue (B10FI), and a plasmid encoding furin were coinjected into muscle of CD‐1 mice, who were treated a day later with STZ to induce diabetes. Electroporation was applied to increase gene transfer. Blood glucose was measured in fed and fasting mice, and fasting plasma insulin was measured by radioimmunoassay. The form of insulin produced and the presence of C‐peptide were analyzed by gel filtration chromatography.
Results
A B10FI plasmid codelivered with a furin plasmid reduced fed and fasting blood glucose levels in STZ‐treated diabetic mice. The (pro)insulin levels in plasma were increased by up to 70‐fold versus blank plasmid‐treated diabetic mice. The administration of FI with furin was less effective. (Pro)insulin levels were greatly increased by using two plasmids carrying different promoter elements (CMV and SV40). Insulin was identified in muscle cells by immunohistochemistry. In plasma, 40–70% of the (pro)insulin was processed to the mature form and free C‐peptide was identified. Insulin gene‐treated mice had improved growth rates and appeared healthier. A single injection of B10FI with SV40Furin DNA increased plasma (pro)insulin for at least 8 weeks and reduced fed blood glucose levels for 5 weeks and fasting levels for 8 weeks.
Conclusions
This is the first report that electroporation‐enhanced intramuscular gene therapy with B10FI can prevent hyperglycemia in murine STZ‐induced diabetes. Gene therapy using various routes and methods of furin‐cleavable insulin gene delivery has been previously explored but, in muscle, results comparable to ours have not been reported. Copyright © 2002 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
The imbalance of Th1/Th2 subsets is an important pathogenic mechanism for insulin-dependent diabetes mellitus (IDDM). Calcitonin gene-related peptide (CGRP) has been found to play important roles in the regulation of T lymphocytes. We hypothesize that exogenous CGRP administration during insulitis m
## Abstract ## Background Intramuscular gene delivery through injection of plasmid DNA has long been considered a promising approach for safe and simple __in vivo__ gene expression for vaccination and gene therapy purposes. Recently, intramuscular gene delivery has been improved by applying low‐vo
## Abstract ## Background Adenosine A1 receptor (A1‐AR) activation can lower plasma glucose in diabetic rats lacking insulin. We investigated the change in A1‐AR gene expression in diabetic rats. ## Methods The incorporation of [U‐^14^C]‐glucose into glycogen was carried out to evaluate the effe
## Abstract The brain neurotransmitters' receptor activity and hormonal pathways control many physiological functions in the body. Acetylcholine (ACh), a major neurotransmitter from autonomic nervous system, regulates the cholinergic stimulation of insulin secretion, through interactions with musca